Literature DB >> 16247182

Failed central nervous system regeneration: a downside of immune privilege?

Ingo Bechmann1.   

Abstract

Immunity is required to eliminate dangerous or degenerated material and to support regeneration, but also causes significant parenchymal damage. In the eye and the brain, in which cornea and lens poorly regenerate and neurons are hardly replaceable, early transplantation experiments demonstrated remarkable tolerance to various grafts. This "immunologically privileged status" (Billingham and Boswell, 1953) may reflect evolutionary pressure to downmodulate certain actions of immune cells within particularly vulnerable tissues. As an example, tolerating certain "neurotrophic" viruses may often be a more successful strategy for survival than the elimination of all infected neurons. While several constitutive and inducible signals maintaining or re-establishing immune tolerance within the brain have been identified, it has also become evident that the resulting anti-inflammatory environment limits certain beneficial effects of neuroinflammation such as neurotrophin secretion or glutamate buffering by T-cells and the clearance of growth-inhibiting myelin or amyloid. Following spinal cord injury, the costs and benefits of neuroinflammation seem to come close because enhancing as well as suppressing innate or adaptive immunity caused amelioration and aggravation of functional regeneration in similar experiments. Evaluating such balances has also begun in (animal models of) Alzheimer's disease, central nervous system trauma, and stroke, and the appreciation of the beneficial side of neuroinflammation has caused a rethinking of the ill-defined use of immune suppressants. As dual roles for individual molecules have been recognized (Merrill and Benveniste, 1996), we are uncovering an already fine-tuned system, but the challenge remains to further support beneficial immune cascades without causing additional damage, and vice versa.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16247182     DOI: 10.1385/NMM:7:3:217

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  119 in total

1.  Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment.

Authors:  J Priller; A Flügel; T Wehner; M Boentert; C A Haas; M Prinz; F Fernández-Klett; K Prass; I Bechmann; B A de Boer; M Frotscher; G W Kreutzberg; D A Persons; U Dirnagl
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 2.  Blood-brain barrier disruption in multiple sclerosis.

Authors:  Alireza Minagar; J Steven Alexander
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

3.  Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

Authors:  Melanie Greter; Frank L Heppner; Maria P Lemos; Bernhard M Odermatt; Norbert Goebels; Terri Laufer; Randolph J Noelle; Burkhard Becher
Journal:  Nat Med       Date:  2005-02-27       Impact factor: 53.440

4.  Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.

Authors:  Phil Edwards; Miguel Arango; Laura Balica; Rowland Cottingham; Hesham El-Sayed; Barbara Farrell; Janice Fernandes; Tamar Gogichaisvili; Nyoman Golden; Bennie Hartzenberg; Mazhar Husain; Mario Izurieta Ulloa; Zouheir Jerbi; Hussein Khamis; Edward Komolafe; Véronique Laloë; Gabrielle Lomas; Silke Ludwig; Guy Mazairac; Maria de los Angeles Muñoz Sanchéz; Luis Nasi; Fatos Olldashi; Patrick Plunkett; Ian Roberts; Peter Sandercock; Haleema Shakur; Caridad Soler; Reto Stocker; Petr Svoboda; Stefan Trenkler; N K Venkataramana; Jonathan Wasserberg; David Yates; Surakrant Yutthakasemsunt
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

Review 5.  Immune privilege and immune regulation in the eye.

Authors:  J Y Niederkorn
Journal:  Adv Immunol       Date:  1990       Impact factor: 3.543

6.  Lymphatic efflux of intracerebrally injected cells.

Authors:  M Oehmichen; H Grüninger; H Wiethölter; M Gencic
Journal:  Acta Neuropathol       Date:  1979-01-12       Impact factor: 17.088

7.  The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans.

Authors:  G J Wright; M Jones; M J Puklavec; M H Brown; A N Barclay
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

Review 8.  Apoptosis in multiple sclerosis.

Authors:  F Zipp
Journal:  Cell Tissue Res       Date:  2000-07       Impact factor: 5.249

9.  Axonal damage induced by invading T cells in organotypic central nervous system tissue in vitro: involvement of microglial cells.

Authors:  U Gimsa; S V Peter; K Lehmann; I Bechmann; R Nitsch
Journal:  Brain Pathol       Date:  2000-07       Impact factor: 6.508

Review 10.  Self-tolerance in the immune privileged CNS: lessons from the entorhinal cortex lesion model.

Authors:  E Kwidzinski; L K Mutlu; A D Kovac; J Bunse; J Goldmann; J Mahlo; O Aktas; F Zipp; T Kamradt; R Nitsch; I Bechmann
Journal:  J Neural Transm Suppl       Date:  2003
View more
  24 in total

Review 1.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

Review 2.  Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain.

Authors:  Burkhard Becher; Ingo Bechmann; Melanie Greter
Journal:  J Mol Med (Berl)       Date:  2006-06-14       Impact factor: 4.599

Review 3.  Perspective is everything: an irreverent discussion of CNS-immune system interactions as viewed from different scientific traditions.

Authors:  Monica J Carson; David D Lo
Journal:  Brain Behav Immun       Date:  2007-01-17       Impact factor: 7.217

4.  Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion.

Authors:  Leman Mutlu; Christine Brandt; Erik Kwidzinski; Birgit Sawitzki; Ulrike Gimsa; Jacqueline Mahlo; Orhan Aktas; Robert Nitsch; Marloes van Zwam; Jon D Laman; Ingo Bechmann
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

Review 5.  From stem cells to oligodendrocytes: prospects for brain therapy.

Authors:  Cui P Chen; Mary E Kiel; Dorota Sadowski; Randall D McKinnon
Journal:  Stem Cell Rev       Date:  2007-12       Impact factor: 5.739

Review 6.  Immunology and neurology.

Authors:  Eilhard Mix; Robert Goertsches; Uwe K Zettl
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

7.  The cellular response in neuroinflammation: The role of leukocytes, microglia and astrocytes in neuronal death and survival.

Authors:  Monica J Carson; J Cameron Thrash; Barbara Walter
Journal:  Clin Neurosci Res       Date:  2006-12

Review 8.  A rose by any other name? The potential consequences of microglial heterogeneity during CNS health and disease.

Authors:  Monica J Carson; Tina V Bilousova; Shweta S Puntambekar; Benoit Melchior; Jonathan M Doose; Iryna M Ethell
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

9.  Long-term retention of ECM hydrogel after implantation into a sub-acute stroke cavity reduces lesion volume.

Authors:  Harmanvir Ghuman; Madeline Gerwig; Francesca J Nicholls; Jessie R Liu; Julia Donnelly; Stephen F Badylak; Michel Modo
Journal:  Acta Biomater       Date:  2017-09-13       Impact factor: 8.947

Review 10.  IDO expression in the brain: a double-edged sword.

Authors:  Erik Kwidzinski; Ingo Bechmann
Journal:  J Mol Med (Berl)       Date:  2007-06-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.